Oral sodium thiosulphate for vascular diseases
with first patented groundbreaking tablet formulation.
Patented
We offer a patented, acid-resistant slow-release formulation
Development
Developed at UMCG / University of Groningen
The Goal
Targeting Raynaud’s syndrome and broader cardiovascular diseases
Roadmap
First milestone: clinical proof-of-concept in Raynaud’s phenomenon
About TSVascular BV
TSVascular BV is a spin-off company from the University Medical Center Groningen (UMCG) and the University of Groningen (RUG). We developed a groundbreaking, patented oral tablet containing sodium thiosulphate (STS) for the treatment of cardiovascular diseases. Our mission is to pioneer new therapies for vascular conditions using a unique slow-release tablet technology.
Our Partners
